Pan‐cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers
The FASEB Journal · 2023-10 · 37 (10)
DOI: 10.1096/fj.202300626r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, online erschienen am 31.08.2023. Verfasst von Xiaofeng Gao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Research Institute/Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xi…. Hauptthemen laut MEDLINE: Cell Cycle Proteins, Neoplasms, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Natural Science Foundation of Hubei Province.
Abstract (Originalsprache)
Sperm‐associated antigen 5 (SPAG5) is a mitotic spindle protein that regulates the separation of sister chromatids into daughter cells. Recent studies have discovered its overexpression in various cancers, suggesting its oncogenic characteristics and functions. However, a comprehensive analysis of SPAG5 regarding its diagnostic, prognostic, and immune‐related effects across different cancer types is lacking. In this study, we employed bioinformatics methods and integrated multiple public databases to explore the potential oncogenic role of SPAG5. We analyzed its expression, prognosis, related chemicals, enriched pathways, immune infiltration, and its impact on different tumor genetic alterations. The results revealed that SPAG5 is highly expressed in most cancers and significantly correlates with poor patient prognosis. Additionally, SPAG5 expression showed potential for early cancer diagnosis in 15 different cancer types. In terms of tumor immunity, high expression of SPAG5 was associated with an immunosuppressive tumor microenvironment and immune therapy efficacy indicators. SPAG5 expression exhibited a negative correlation with most immune cell infiltrates but demonstrated a significant positive correlation with Th2 cells and MDSC cells. Multicolor fluorescence immunohistochemistry demonstrated that SPAG5 activates immune cell populations within tumors, indicating its significant role in the tumor microenvironment. Enrichment analysis indicated that SPAG5‐related genes are mainly involved in cell cycle, cellular senescence, P53 signaling pathway, and FoxO signaling pathway. Furthermore, we confirmed the high expression of SPAG5 in cancer cells and observed that its knockdown upregulated the expression of the p53 protein. In conclusion, SPAG5 holds value as a diagnostic, prognostic, and immune biomarker in various cancers and may provide a novel target for tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicine Research Institute/Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning, People's Republic of China.
- School of Basic Medical Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, People's Republic of China.
- College of Biology, Hunan University, Changsha, People's Republic of China.
- School of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, People's Republic of China.
ORCID-Profile: Xiaofeng Gao, Huitong Bu, Xuzheng Gao, Ying Wang, Long Wang, Zhenwang Zhang
Förderung
- Natural Science Foundation of Hubei Province
Zitieren
APA
Gao, X., Bu, H., Gao, X., Wang, Y., Wang, L., & Zhang, Z. (2023). Pan‐cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers. The FASEB Journal, 37(10). https://doi.org/10.1096/fj.202300626r
Vancouver
Gao X, Bu H, Gao X, Wang Y, Wang L, Zhang Z. Pan‐cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers. The FASEB Journal. 2023;37(10). doi:10.1096/fj.202300626r
BibTeX
@article{Gao2023,
author = {Gao, Xiaofeng and Bu, Huitong and Gao, Xuzheng and Wang, Ying and Wang, Long and Zhang, Zhenwang},
title = {Pan‐cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers},
journal = {The FASEB Journal},
year = {2023},
volume = {37},
number = {10},
doi = {10.1096/fj.202300626r}
}
EUVIMED